Lymphocyte Activation Gene - 3Protein Market Drivers
Several drugs in clinical trialsthat target the LAG-3 protein, is expected to be a major factor contributing inglobal LymphocyteActivation Gene - 3 Protein Market growth over the forecast period. Thesedrugs are still in the clinical trials in different phases. For instance, in2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combinationwith Opdivo (nivolumab), effectively aided in treatment of advanced melanomathat was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phaseII clinical trial and its estimated study completion date is March 16, 2022.
Immune checkpoint receptors suchas lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface ofeffector T cells and regulatory T cells (Tregs). T cells are a type of whiteblood cells that eliminate unhealthy or foreign cells that enter the immunesystem. Function of lymphocyte activation gene - 3 protein is to control T cellresponse, activation, and growth. Lymphocyte activation gene - 3 turns off theimmune response when a T cell is activated to eliminate a target cell. Thisprevents the T cells from harming healthy cells. Moreover, lymphocyteactivation gene - 3 protein is associated with T cell exhaustion in which the Tcells become desensitized and lose their ability to function.
LAG-3 is closely associated withregulation of cytotoxic T cells and regulatory T cells, which has attractedattention of researchers and manufacturers as a therapeutic target againstcancer. In cancers, lymphocyte activation gene - 3 expressing exhaustedcytotoxic t cells and regulatory T cells (Tregs) are found to be gathered attumor locations. Recent studies reported that inhibiting LAG-3 functions allowsT cells to regain their cytotoxic function and affect tumor growth. There areseveral LAG-3 protein antibodies in the clinical trials, which are expected tofurther advance in clinical trials over the forecast period.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2027
Moreover, several other drugssuch as MGD013 sponsored by MacroGenics (estimated study completion date -August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated studycompletion date is August 2019) that are in Phase 1 clinical trials, isexpected to be a major factor contributing in global LAG-3 protein market growthover the forecast period.
Manufacturers and researchers arefocused on development of novel therapies that aid in treatment of cancer. Highprevalence of cancer is expected to boost growth of the market. According toNational Cancer Institute, around 1,735,350 new cases of cancer are expected tobe diagnosed in the U.S., in 2018. The most common types of cancer are lungcancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others.According to Cancer Research UK, 2015, around 54,900 new cases of breast cancerare registered in the UK, which account for 15% of all new cancer cases, annually.
However, uncertainty of clinicaltrials (as drugs may fail to show efficacy even in late phases of clinicaltrials) is expected to restrain the lymphocyte activation gene - 3 proteinmarket growth over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/lymphocyte-activation-gene-3-protein-market-2027
Lymphocyte Activation Gene - 3 ProteinMarket Regional Insights
North America is expected towitness significant growth in the LAG -3 protein market over the forecastperiod. Robust pipeline of LAG-3 protein antibodies and the increasing demandfor such drugs is expected to facilitate growth of the market, in the U.S. Forinstance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials andRegeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 inphase I clinical trials, 2017.
High prevalence of various typesof cancer in North America, Europe, and Asia Pacific region is expected to be amajor factor contributing growth of the lymphocyte activation gene - 3 proteinmarket over the forecast period. According to European Union (EU), in 2014,almost 1/3rd million people died from cancer in the EU-28. Moreover,manufacturers are focused on conducting clinical trials in these regions toexpand their potential customer base.
Lymphocyte Activation Gene - 3Protein Market Key Player
Key players operating in theglobal lymphocyte activation gene - 3 protein market include, Bristol-MyersSquibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc.,GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., SutroBiopharma Inc., Symphogen A/S, and Immutep Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2027
AboutCoherent Market Insights:
Coherent MarketInsights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
